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The malaria testing and treatment
market in Kinshasa, Democratic Republic of the
Congo, 2013
ACTwatch Group1*, Godéfroid Mpanya2*, Antoinette Tshefu3 and Joris Losimba Likwela4
Abstract
Background: The Democratic Republic of Congo (DRC) is one of the two most leading contributors to the global
burden of disease due to malaria. This paper describes the malaria testing and treatment market in the nation’s capital
province of Kinshasa, including availability of malaria testing and treatment and relative anti-malarial market share for
the public and private sector.
Methods: A malaria medicine outlet survey was conducted in Kinshasa province in 2013. Stratified multi-staged sampling
was used to select areas for the survey. Within sampled areas, all outlets with the potential to sell or distribute anti-malarials
in the public and private sector were screened for eligibility. Among outlets with anti-malarials or malaria rapid diagnostic
tests (RDT) in stock, a full audit of all available products was conducted. Information collected included product information
(e.g. active ingredients, brand name), amount reportedly distributed to patients in the past week, and retail price.
Results: In total, 3364 outlets were screened for inclusion across Kinshasa and 1118 outlets were eligible for the
study. Among all screened outlets in the private sector only about one in ten (12.1%) were stocking quality-assured
Artemisinin-based Combination Therapy (ACT) medicines. Among all screened public sector facilities, 24.5% had both
confirmatory testing and quality-assured ACT available, and 20.2% had sulfadoxine-pyrimethamine (SP) available for
intermittent preventive therapy during pregnancy (IPTp). The private sector distributed the majority of anti-malarials
in Kinshasa (96.7%), typically through drug stores (89.1% of the total anti-malarial market). Non-artemisinin therapies
were the most commonly distributed anti-malarial (50.1% of the total market), followed by non quality-assured ACT
medicines (38.5%). The median price of an adult quality-assured ACT was $6.59, and more expensive than non qualityassured ACT ($3.71) and SP ($0.44). Confirmatory testing was largely not available in the private sector (1.1%).
Conclusions: While the vast majority of anti-malarial medicines distributed to patients in Kinshasa province are sold
within the private sector, availability of malaria testing and appropriate treatment for malaria is alarmingly low. There
is a critical need to improve access to confirmatory testing and quality-assured ACT in the private sector. Widespread
availability and distribution of non quality-assured ACT and non-artemisinin therapies must be addressed to ensure
effective malaria case management.
Keywords: Democratic Republic of the Congo, Artemisinin-based combination therapy, ACT, Rapid diagnostic test,
Market share, Availability antimalarial
Background
The Democratic Republic of Congo (DRC) is the second largest contributor to the global burden of disease
*Correspondence: gmpanya@psicongo.org; mlittrell@psi.org
2
Association de Santé Familial, 4630 Avenue de la Science, Immeuble
USTC, Bloc C, Gombe, Kinshasa, Democratic Republic of Congo
Full list of author information is available at the end of the article

due to malaria [1]. Malaria accounts for more than 40%
of all outpatient visits and is the main cause of morbidity
and mortality [1]. Of notable public health concern is the
capital city of Kinshasa, which hosts up 15% of the DRC’s
79 million people [2]. Malaria prevalence is diverse given
the geographical make-up of the city, with densely populated areas separated by large semi-rural areas, and with
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some of the areas completely rural in nature [3]. Recent
evidence suggests malaria prevalence is around 11.9% in
children 6–59 months, and as high as 31.7% in semi-rural
areas of the city [3], illustrating not only the diversity of
malaria prevalence and risk in Kinshasa, but that malaria
is of grave public health concern in this populous area, a
finding supported by earlier research [4, 5].
Ensuring that febrile patients in Kinshasa have access
to confirmatory malaria testing and affordable artemisinin-based combination therapy (ACT)—the first-line
treatment for uncomplicated malaria—will be central to
ensuring patients are managed correctly in accordance
with the national malaria control guidelines. The DRC
malaria treatment guidelines state that all suspected
cases should be confirmed by diagnostic testing prior
to treatment. Positive cases of simple malaria should
be treated with artesunate + amodiaquine (ASAQ) or
artemether + lumefantrine (AL), ideally with a World
Health Organization (WHO) pre-qualified product,
referred to as a quality-assured ACT.
A 2009 survey conducted by the ACTwatch project [6]
revealed that there are several barriers to appropriate
treatment in the DRC—namely that availability of quality-assured ACT medicines in the private sector, where
most people seek treatment, is low (Table 1) [7]. In 2009,
only 14% of the anti-malarial stocking private sector had
quality-assured ACT available. Furthermore, ACT medicines that were available in the private sector were namely
non quality-assured. Oral artemisinin monotherapy was
sold and distributed in the private sector, and contributed up to 10% of the total market share of all anti-malarials. Due to the threat that oral artemisinin monotherapy
Table 1 Key results from 2009 ACTwatch survey in Kinshasa
Dates of data collection

August–September
2009

Sample

N

Outlets screened

2368

Outlets interviewed

778

Among all screened outlets, percentage that
had

% (95% CI)

Public sector availability of quality-assured ACT

48.5 (32.8, 64.6)

Private sector availability of quality-assured ACT

14.1 (10.6, 18.6)

Public sector availability of non quality-assured ACT 20.0 (11.4, 32.8)
Private sector availability of non quality-assured
ACT

60.7 (55.2, 66.0)

Public sector availability of oral artemisinin monotherapy

26.0 (15.4, 40.3)

Private sector availability of oral artemisinin monotherapy

70.4 (65.4, 75.0)

Anti-malarial market share

%

Market share of oral artemisinin monotherapy

10.8

poses for the development of artemisinin resistance, this
class of anti-malarial medicine was banned in the DRC in
2009 [1]. Finally, availability of malaria diagnosis was low
in the private sector and restricted to private for-profit
health facilities (21%). Availability was higher in the public sector, with around 80% of this sector stocking a diagnostic test.
In 2013, a follow-up outlet survey was conducted in
Kinshasa to understand the extent to which the antimalarial landscape has changed over time. The paper provides a descriptive illustration of Kinshasa’s anti-malarial
market as a means to understand current barriers regarding access to appropriate malaria case management
and to guide future malaria interventions designed to
improve access to affordable quality-assured ACT and
confirmatory testing.

Methods
The ACTwatch project is a multi-country research project implemented by Population Services International
(PSI) and was launched in 2008 [6]. The ACTwatch project provides information on anti-malarial market evidence to inform case management strategies, and to
monitor national and global policy and funding decisions
[8, 9]. Outlet survey data are collected to understand the
supply side of malaria medicine and diagnostic markets
[10].
Design and sample

A sub-national representative cross-sectional malaria
medicine outlet survey was conducted in Kinshasa
(11th September—11th October 2013). Methods for
the surveys have been described in detail previously [6,
9]. Briefly, clusters with a population size of approximately 10,000 to 15,000 inhabitants, (“aires de santé”)
were selected with probability proportional to size from
a list of all clusters in Kinshasa province. Explicit stratification was used to sample from urban and rural areas
of the province. All outlets with the potential to provide
malaria medicine or testing were screened within each
cluster to determine availability of malaria diagnostics
and medicines. In the public sector, this included public health facilities and not-for-profit health facilities. In
the private sector, this included private for-profit health
facilities, pharmacies, drug stores, general retailers and
itinerant drug vendors. Outlets were included in the survey if they had an anti-malarial in stock, or anti-malarials
in stock in the past three months preceding the survey, or
had malaria testing available.
The study was powered to detect a minimum of a
20% point change in availability of quality-assured ACT
among anti-malarial stocking outlets with 80% power
and 95% significance.
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Procedures

Outlets were identified using a census procedure within
each of the selected clusters. All outlets were approached
and administered a set of screening questions to determine eligibility. Outlets were eligible if they had an antimalarial in stock on the day or survey or in the past three
months. An interview with the staff member who was
most likely to sell or prescribe medications was conducted. The interview was carried out in French or in
local language (Lingala).
Measures

A structured questionnaire included an audit of all available anti-malarials and malaria rapid diagnostic tests
(RDTs). The audit captured product information including formulation, strength, brand name, active ingredients,
manufacturer, and country of manufacture. Information
was also collected on the retail price and the amount of
the medicine sold in the last week, or number of RDTs
performed in the past week. Availability, price and number of tests performed by microscopy was also collected.
Data analysis

Double data entry was conducted using Microsoft Access
(Microsoft Corporation, Redmond, Washington, USA)
with built-in range and consistency checks. Data were
analyzed across survey rounds using Stata (StataCorp
College Station, TX). Stata survey settings were used to
account for the stratified and clustered sampling strategy and to apply sampling weights. Sampling weights
were calculated as the inverse of the probability of cluster
selection.
Standard indicators were constructed according to
definitions applied across the ACTwatch project and
have been described elsewhere [20, 21]. For all key
indicators, anti-malarials were categorized as ACT,
non-artemisinin therapy or artemisinin monotherapy
according to active ingredients. Artemisinin monotherapies were further classified as oral or non-oral to
distinguish between the banned oral artemisinin monotherapies, and the non-oral artemisinin monotherapies,
which may be used for treatment of severe malaria. ACT
medicines were further classified as quality-assured or
non quality-assured according to product information
including active ingredients, strengths, manufacturer
and country of manufacture. This product information
was matched to lists of pre-qualified ACT medicines
from the WHO and the Global Fund to identify qualityassured ACT that are manufactured according to global
quality standards. Non quality-assured ACT medicines
are defined as ACT medicines that do not have WHO
pre-qualification or approval for procurement by the
Global Fund.
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Availability was determined according to the physical
presence of anti-malarial medicines during the product audit. Anti-malarial availability was measured as the
percent of outlets with each type of anti-malarial noted
above in stock on the day of the survey. The volumes of
the anti-malarials distributed were standardized using
the adult equivalent treatment dose (AETD) to allow calculation of relative market share for types of anti-malarials, including tablet and all non-tablet dosage forms.
The AETD is defined as the amount of active ingredient
required to treat an adult weighing 60 kg according to
WHO treatment guidelines [22]. Provider reports on the
amount of the drug sold or distributed during the week
preceding the survey were used to calculate volumes
distributed. Relative market share was calculated as the
amount of anti-malarial medicine distributed in the past
week within each anti-malarial drug category (qualityassured and non quality-assured ACT, non-artemisinin
therapy, oral artemisinin monotherapy, and non-oral
artemisinin monotherapy), divided by the total antimalarial distribution.
The AETD was also used for comparing the median
private sector price for different anti-malarial medicines.
Price was calculated for tablet formulation only given
the difference in price across drug formulation. Provider
reports for retail prices were converted to US dollars
using official exchange rates. Median price and the interquartile range were calculated.

Results
In total, 3364 outlets were screened for inclusion across
Kinshasa and 1118 eligible outlets were interviewed and
included in the analysis. Outlets stocking anti-malarials
included public and private not-for-profit and for-profit
health facilities, pharmacies, and drug stores. More than
2100 general retail outlets were screened, however antimalarial medicines were not found in the general retail
sector (Table 2). Of the outlets screened, 141 facilities had only diagnostic testing available and were not
included in the analysis. Among outlets with anti-malarials in stock on the day of interview, 12,291 anti-malarial
products were audited. In total, 278 RDT products were
audited.
All public and private health facilities and pharmacies
and 98.6% of drug stores stocking anti-malarial medicines reportedly employed a provider who completed
secondary school. In addition, all public health facilities
and pharmacies, nearly all private not-for-profit (99.5%)
and for-profit health facilities (99.7%), and 82.2% of drug
stores reportedly employed a provider with a formal
health qualification in medicine, pharmacy, nursing, midwifery or community health work (see Additional file 1:
Table S1).
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Table 2 Results of the outlet census
N

Outlets screened

Public sector

Private sector

Public
facility

Private forprofit facility

Private not-forprofit facility

Pharmacy

Drug
store

General
retailer

Itinerant
drug vendor

3364

26

66

367

3

741

2149

12

962

21

41

174

3

722

1

0

45

4

6

28

0

10

0

0

142

4

16

122

0

0

0

0

932

21

41

173

3

693

1

0

Malaria testing availablea

45

1

6

28

0

10

0

0

Malaria testing available

141

4

16

121

0

0

0

0

109

169

815

85

11,111

2

0

8

13

54

1

3

0

0

Eligible outlets
Anti-malarial in stock
Anti-malarial in stock in the past
3 monthsa
Malaria testing availablea
Outlets interviewed
Anti-malarial in stock in the past
3 monthsa

Products audited
Anti-malarials

12,291

Malaria RDTs
a

278

No anti-malarials in stock on the day of the survey

100

Public health facility
Private not-for-profit health
facility
Private for-profit health
Facility
Pharmacy
Drug shop
General retailer

Fig. 1 Anti-malarial market composition

PERCENT OF OUTLETS

N=962

90
80
70
60
50
40
30
20
10
0

Public
Sector
Total
N=62

Private
for-profit
health facility,
N=172

Drug
shop
N=693

QACCT

Non-QA ACT

SP

Oral quinine

Private
Sector
Total
N=869

Oral artemisinin monotherapy

Fig. 2 Anti-malarial availability among anti-malarial stocking outlets

Anti‑malarial market composition

Figure 1 shows the relative distribution of all outlets that
had at least one anti-malarial in stock (n = 917). The antimalarial market in Kinshasa was dominated by the private sector, and in particular by drug stores. Drug stores
accounted for 80% of anti-malarial-stocking outlets in
2013, while private for-profit health facilities comprised
15% of the market. The public sector (public health facilities and private not-for profit facilities), accounted for
less than 5% of the market composition.
Availability of anti‑malarials

Figure 2 shows availability of different classes of antimalarials as the proportion of anti-malarial stocking

outlets. Among the anti-malarial stocking public sector, 49.7% had quality-assured ACT in stock compared
to 12.1% in the private sector. Within the anti-malarial
stocking private sector, less than 10% of drug stores
and only one in five private for-profit health facilities (24.7%) were found to stock quality-assured ACT.
Availability of non quality-assured ACT medicines was
much higher in the private sector. Over 80% of private sector outlets stocked non quality-assured ACT
compared to 23.2% among public sector outlets. Non
quality-assured ACT was commonly available in antimalarial-stocking drug stores (90.5%), and private-for
profit health facilities showed moderate availability

ACTwatch Group et al. Malar J (2017) 16:94
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(44.0%). Non-artemisinin therapies were more commonly available in the private sector (typically sulfadoxine-pyrimethamine [SP] 65.4%; oral quinine
84.6%) as compared with the public sector (SP, 34.9%;
oral quinine 52.6%). Availability of oral artemisinin
monotherapy was <1% in the private sector and 0% in
the public sector.
Anti‑malarial market share

Figure 3 shows the relative anti-malarial market share
for public and private sector and by type of anti-malarial medicine. Ninety-seven percent of all anti-malarials
distributed to consumers in the week preceding the survey were distributed through the private sector. Most of
the anti-malarials were distributed through drug stores
(89.1% of the total anti-malarial market share).
Non-artemisinin therapies were the most commonly
distributed anti-malarial (50.1% of the total market
share). These included SP (31.1%) and quinine (19.0%).
Non quality-assured ACT medicines accounted for 38.5%
of all anti-malarials distributed. Quality-assured ACT
medicines accounted for less than 5% of the total market share. Oral artemisinin monotherapy market share
was <0.1%.
Non quality‑assured ACT in the private for‑profit sector

Figure 4 presents the frequency distribution by generic
type and formulation of the 5982 non quality-assured
ACT medicines audited in the private sector. Most

non quality-assured ACT medicines available were
artemether-lumefantrine (AL) suspensions (38%, 18
unique brands), AL tablets (31%, 15 unique brands)
or suspensions (11%, 7 unique brands). Other types
of non quality-assured ACT medicines included
dihydroartemisinin-piperaquine tablets (5%, 5 unique
brands) and suspensions (9%, 6 unique brands); as well
as dihydroartemisinin-SP tablets (3%, 1 brand) and
artesunate-amodiaquine tablets (3%, 5 unique brands).
Price of anti‑malarials

The median [inter-quartile range] price in drug shops
for one adult equivalent treatment dose of qualityassured ACT was $6.59 [$2.75–$9.89], compared to $3.85
[$3.30–$4.94] for non quality-assured ACT. The median
quality-assured ACT price in private for-profit facilities
was $0.00, while non quality-assured ACT was on average sold at $3.71 [$2.75–$4.94]. SP was the cheapest tablet
anti-malarial in the private for-profit sector ($0.44 [$0.33–
$0.55] for one AETD).
Readiness for malaria case management: availability
of quality‑assured ACT and malaria diagnosis,
and availability of intermittent preventive therapy
during pregnancy (IPTp)

Table 3 summarizes availability of key commodities for
appropriate malaria case management and for provision
of IPTp among all screened outlets (including outlets
with and without anti-malarials on the day of the survey),

100

PERCENT MARKET VOLUME

90
80
70
60
50
40
30
20
10
0

Public
Sector
Total

Private
Sector
Total

Private
for-profit
health facility

Pharmacy

Drug
store

General
retailer

Quality-assured ACT

Non quality-assured ACT

SP

Other non-artemisinin therapy

Oral artemisinin monotherapy

Non-oral artemisinin monotherapy

Fig. 3 Anti-malarial market share
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Fig. 4 Distribution of non quality-assured ACT available in the private sector, 2013.
Notes Types of non quality-assured ACT audited in private sector outlets by generic type and dosage form, Kinshasa 2013 (n = 5,982, unweighted).
Other generic tablets audited but comprising <1% total share were artesunate-mefloquine, dihydroartemisininpiperaquine-trimethoprim and
artemisinin-piperaquine. AL artemether-lumefantrine; AS-SP artesunate-SP; DHA-PPQ dihydroartemisinin-piperaquine; ASAQ artesunate-amodiaquine. asterisk The unique brand counts does not differentiate tablet strengths or age/weight bands for the same branded product (e.g. Brand X of
AL 20mg/120mg and Brand X of AL 40mg/240mg are counted as one unique brand, brand X).

Table 3 Readiness for malaria case management in the public and private sector, among all screened outlets
Percent (95% confidence interval [CI])
Total Public Sector

Private for-profit
health facility

Drug store

Total Private Sector

N = 92

N = 367

N = 741

N = 3272

Any malaria blood testing

86.8 (75.9, 93.2)

75.5 (64.9, 83.7)

0.3 (0.1, 1.5)

7.3 (6.1, 8.7)

Malaria microscopy

82.9 (72.0, 90.2)

72.9 (62.8, 81.1)

0.0

7.0 (5.8, 8.3)
1.4 (1.0, 2.0)

RDT

21.8 (12.3, 35.8)

14.0 (10.3, 18.7)

0.3 (0.1, 1.4)

Quality-assured ACT

28.7 (17.5, 43.2)

12.5 (8.2, 18.5)

8.6 (5.5 13.2) 3.3 (2.5, 4.4)

Readiness for malaria case management:
Malaria testing and quality-assured ACT available

24.5 (15.0, 39.6)

10.7 (7.2, 15.6)

0.3 (0.1, 1.5)

1.1 (0.7, 1.7)

Readiness for IPTp:
SP available

20.2 (11.7, 32.5)

12.0 (8.1, 17.5)

N/a

N/a

as a means to show the extent to which different outlet
types are able to provide nationally recommended case
management commodities.
Public sector readiness for malaria case management was overall low with only one in four public

sector outlets stocking both malaria testing and quality-assured ACT (24.5%). While availability of confirmatory testing was high (86.8%), availability of
quality-assured ACT was much lower (28.7%). Availability of SP for ITPp was also low; only one in five
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public facilities had SP available on the day of the survey (20.2%).
In the private sector, only 1.1% of outlets had both
confirmatory testing and quality-assured ACT available.
Readiness was higher among private for-profit facilities
(10.7%) as compared with drug stores (0.3%).

Discussion
Data from a 2013 representative medicine outlet survey
in Kinshasa confirm the importance of the private sector
as a source of anti-malarial treatment, particularly drug
stores. Results suggest urgent need to address malaria
case management in the private sector, remove non quality-assured ACT medicines and inefective nonartemisinintherapies from the market, and address gaps in public
sector readiness for appropriate case management.
Urgent need to address malaria case management in the
private sector

The distribution of anti-malarials in Kinshasa in 2013 was
heavily dominated by the private sector, particularly drug
stores which comprised almost 90% of the anti-malarial
service delivery points. Drug stores in Kinshasa are not
registered or regulated by a government authority, and
are not authorized to test for malaria using RDTs. However, the vast majority of people receiving anti-malarial
treatment in Kinshasa are receiving medicines from these
unregistered and unregulated points of care where confirmatory testing is not permitted and quality-assured
ACT treatment and malaria diagnostic testing is generally not available. With the vast majority of the antimalarial distribution moving through drug stores, these outlets
most commonly stock and distribute non quality-assured
ACT medicines and non-artemisinin therapies.
The finding that most of the anti-malarial medicine
market share is comprised of drug stores in Kinshasa may
provide an opportunity to increase access to affordable,
quality-assured ACT medicines, as evidenced in other
countries where these facilities are a common source
of treatment [11–13]. The affordable medicines facility,
malaria (AMFm), a large scale pilot to increase access to
subsidized quality-assured ACT, demonstrated significant improvements in availability, affordability and relative market share for these medicines among the private
sector and in drug stores in particular [14]. Since the
AMFm pilot, follow-up ACTwatch surveys have shown
a sustained improvement in the availability of qualityassured ACT medicines among drug stores in these
countries [11–13]. The success of the private sector copayment mechanism in these countries suggests that a
similar strategy could be effective in improving the availability, affordability and market share for quality-assured
ACT in Kinshasa.
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Several countries have implemented successful interventions aimed at specifically strengthening drug stores
for malaria case management. In Nigeria, Tanzania
and Uganda, registration or accreditation programmes
have been implemented in recent years to ensure that
drug store providers are trained to assess and treat suspected malaria. For example, since 2006 the Tanzanian
government has been in the process of accrediting drug
dispensing outlets (ADDOs) to sell a limited range of
prescriptions only medicines, including quality-assured
ACT, after participation in a 35-day training programme.
More recently, pilot initiatives have introduced RDTs into
ADDOs with relative success, demonstrating patient willingness to pay for an RDT and an increased likelihood to
purchase an ACT medicine [15]. Other research shows
similar findings from a pilot test in Uganda where RDTs
were introduced among drug stores that were licensed
by the Ugandan Ministry of Health. The study concluded
that by offering provider training and access to subsidized
RDTs, it was possible to increase malaria testing rates significantly within communities [16]. These programmes
demonstrate the feasibility of providing confirmatory
testing and quality-assured ACT at these common points
of care for suspected malaria, which is a common source
of treatment in Kinshasa—as evidenced by other studies [17]. Approaches to engaging drug stores in Kinshasa
with accreditation or other registration, training and
supervision programmes could be promising for increasing coverage of confirmatory testing prior to treatment
and improving access to quality-assured ACT.
Widespread availability and distribution of inappropriate
anti‑malarial medicines

In 2009, the vast majority of anti-malarial-stocking outlets in Kinshasa were stocking oral artemisinin monotherapy. By 2013, oral AMT had disappeared from the
market, demonstrating the success of the drug ban which
had been implemented in 2009 [18].
Despite this achievement, multiple threats to effective
malaria case management persist in the anti-malarial
market in 2013. First is the widespread availability of non
quality-assured ACT medicines. These are combination
therapies that are not manufactured according to global
standards set by the World Health Organization [19] and
include up to 57 different brands with a spectrum of different formulations and active ingredients, though most
commonly were either AL suspensions or tablets. While
it was beyond the scope of this study to test the drug
quality and efficacy of these products, the availability of
multiple generics, formulations and brands which do not
conform to global quality standards is of concern given
the threats to effective parasite clearance and potential to
contribute to artemisinin resistance.
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The availability and distribution of non quality-assured
ACT medicines is a growing problem documented in
other countries by the ACTwatch project, including
Kenya and Nigeria [20, 21]. However, levels of availability
and distribution are much higher in Kinshasa and this is
of particular concern given the significant malaria burden
in the DRC. Non quality-assured products are commonly
manufactured in the DRC and such locally-manufactured
ACT medicines may also be prone to a number of risk
factors for sub-standard quality, such as poor drug regulation and technical capacity in their development [22].
Given their lack of quality-assured status, these medicines have not been subjected to international good
manufacturing practices and may have contents or dissolution times that are outside the acceptable limits due
to poor quality control [23]. Other research that tested
ACT formulations for their drug quality has shown that
quality-assured ACT medicines have 0.1 times the odds
of being poor quality compared with non quality-assured
ACT (0.5% of quality-assured ACT tested were of poor
quality compared to 5.4% of those non quality-assured
ACT). Additional analysis revealed that products with
quality-assured status remained significantly associated
with anti-malarial medicine being of acceptable quality
[24]. The results indicate that important improvements
in quality can be achieved by ensuring that only products meeting WHO prequalification are registered and
allowed on the market. The replacement of non qualityassured ACT with quality-assured ACT from the Kinshasa market will be important to ensure febrile children
and adults have access to effective, first-line treatment.
The 2013 outlet survey also documented ongoing high
levels of availability and distribution of non-artemisinin
therapies, which are no longer recommended for uncomplicated malaria case management in the DRC. Non-artemisinin therapies accounted for half of all anti-malarials
distributed in Kinshasa. These include oral quinine and
SP. Although SP may be used for IPTp, availability and
distribution through drug stores as opposed to health
facilities, as well as product packaging and patient
instructions on SP products promoting use for malaria
case management for people of all ages, suggests that
SP is being used as an inexpensive treatment for malaria
[25]. The results also demonstrate that SP is far less
expensive than quality-assured ACT in the private sector. These results point to the need to replace ineffective
and non-recommended non-artemisinin therapies with
quality-assured ACT medicines. The aforementioned
AMFm pilot is one strategy which has shown promise in
reducing stockage and distribution of non-artemisinin
therapies, however challenges with availability and distribution of these products persist in the former AMFm
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countries given the relatively low cost of non-artemisinin
monotherapies [26].
Gaps in public and private sector readiness to manage
malaria

The DRC was one of the first countries to adopt the second edition of the World Health Organization’s malaria
treatment guidelines [27], for which a cornerstone of
these guidelines was the recommendation to provide
confirmatory diagnostic testing for all febrile patients,
even in children under the age of five. Results from the
2013 outlet survey in Kinshasa demonstrate that nearly
90% of public facilities in Kinshasa have confirmatory
testing available, primarily through malaria microscopy
as opposed to RDTs. However, significant gaps persist in
availability of quality-assured ACT, with fewer than onethird of public sector outlets stocking quality-assured
ACT. Overall, only one in four public sector outlets have
both confirmatory testing and quality-assured ACT available. Only one in five public outlets had SP available for
IPTp during antenatal care visits.
Kinshasa’s readiness for appropriate malaria case management was extremely low in the private sector, and
in particular among drug stores where most patients
receive anti-malarial treatment. In drug stores, there
was negligible availability of diagnostic tests and quality-assured ACT, pointing to the need to reinforce and
promote the necessity of diagnostic testing among both
providers and patients, while ensuring commodities
are available and affordable within this sector as well as
the public sector. Low availability of confirmatory testing in particular threatens appropriate management of
suspected cases, spurring the potential for presumptive
anti-malarial treatment. The low availability of confirmatory testing also merits a revisit of national policy to
permit testing within these outlet types and provision of
quality-assured treatment. As discussed previously, several initiatives in other countries have introduced RDTs
into drug stores with relative success [15, 16], demonstrating the feasibility of providing confirmatory testing
in the private sector.
Implications

Given significant gaps in readiness for malaria case
management documented in 2013, several measures
were taken by the National Malaria Control Programme
(PNLP), and with support from the Department For
International Development (DFID), GFTAM, Association de Santé Familiale (ASF) and Population Services
International (PSI), to transform the private sector antimalarial market to improve quality malaria case management in Kinshasa [28]. This has included improving
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coordination between authorities and strengthening of
the regulatory environment, establishing price reductions
and increasing consumer demand for quality-assured
ACT and fostering private sector case management.
Over three and a half million quality-assured, subsidized
ACT courses have been delivered over the course of the
project and a further 1.7 million RDT. It is expected that
future ACTwatch surveys will be able to document these
achievements.

Limitations
The data presented in this paper are representative for
Kinshasa province only. Given the importance of the
DRC with respect to global malaria burden, a key limitation is the lack of information on malaria markets in
other areas of the DRC. Other limitations to the ACTwatch survey methodology have been described elsewhere in detail [10].
Conclusions
While incredible progress has been made in recent
years in improving access to malaria testing and quality-assured first-line treatment in many countries in
sub-Saharan Africa [1], progress in the DRC has largely
been absent. Given the significant burden of malaria in
this country, there is urgent need to address gaps in both
the public and private sector. Evidence from this study
suggests that working with the private sector to remove
non quality-assured ACT medicines and ineffective nonartemisinin therapies and to increase the availability and
quality-assured ACT and confirmatory testing will be
necessary to ultimately improve malaria case management in Kinshasa.
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